Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

Background: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. Methods: A retrospective, multi-center, provincial cohort database was used to investigate the relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Taylor E., Stukalin, Igor, Ding, Philip Q., Goutam, Siddhartha, Sander, Michael, Ewanchuk, Benjamin, Cheung, Winson Y., Heng, Daniel Y. C., Cheng, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605250/
https://www.ncbi.nlm.nih.gov/pubmed/37887546
http://dx.doi.org/10.3390/curroncol30100646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605250/
https://www.ncbi.nlm.nih.gov/pubmed/37887546
http://dx.doi.org/10.3390/curroncol30100646

Ejemplares similares